Pfizer's Pipeline Hopes Offset Revenue Risks: Fair Value Edges Up
Baca dalam 60 detik
- Pfizer faces a revenue cliff as COVID-19 vaccine and Paxlovid sales plummet, with 2024 forecasts showing a 30% drop from peak levels.
- The company counters with a robust pipeline featuring 15 late-stage trials, including potential blockbusters in RSV vaccines and cancer therapies.
- Analysts project these new drugs could add $10 billion in annual sales by 2028.
Pfizer faces a revenue cliff as COVID-19 vaccine and Paxlovid sales plummet, with 2024 forecasts showing a 30% drop from peak levels. The company counters with a robust pipeline featuring 15 late-stage trials, including potential blockbusters in RSV vaccines and cancer therapies. Analysts project these new drugs could add $10 billion in annual sales by 2028.
The market's muted fair value adjustment suggests skepticism about execution risk. Pfizer's $43 billion Seagen acquisition bolsters oncology, but integration challenges loom. Patent expirations on key drugs like Eliquis and Xeljanz threaten to erode $8 billion in revenue by 2026.
Despite these headwinds, Pfizer's dividend yield of 5. 8% attracts income-focused investors. The company's cost-cutting program targets $4 billion in savings by 2025, improving margins.
Power Move: Pfizer's narrative shift hinges on pipeline execution against revenue erosion. Success in late-stage trials could trigger a re-rating, but failure would expose the stock to further downside. Investors should monitor Phase 3 readouts for RSV and obesity candidates as key catalysts.
This article was edited with AI assistance for readability. Read original here.
